Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity

IF 12 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Jacc: Cardiooncology Pub Date : 2024-04-01 DOI:10.1016/j.jaccao.2023.12.009

Hanne M. Boen MD , Martina Cherubin MSc , Constantijn Franssen MD, PhD , Andreas B. Gevaert MD, PhD , Isabel Witvrouwen MD, PhD , Matthias Bosman PhD , Pieter-Jan Guns PhD , Hein Heidbuchel MD, PhD , Bart Loeys MD, PhD , Maaike Alaerts PhD , Emeline M. Van Craenenbroeck MD, PhD

{"title":"Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity","authors":"Hanne M. Boen MD , Martina Cherubin MSc , Constantijn Franssen MD, PhD , Andreas B. Gevaert MD, PhD , Isabel Witvrouwen MD, PhD , Matthias Bosman PhD , Pieter-Jan Guns PhD , Hein Heidbuchel MD, PhD , Bart Loeys MD, PhD , Maaike Alaerts PhD , Emeline M. Van Craenenbroeck MD, PhD","doi":"10.1016/j.jaccao.2023.12.009","DOIUrl":null,"url":null,"abstract":"<div><p>Close monitoring for cardiotoxicity during anthracycline chemotherapy is crucial for early diagnosis and therapy guidance. Currently, monitoring relies on cardiac imaging and serial measurement of cardiac biomarkers like cardiac troponin and natriuretic peptides. However, these conventional biomarkers are nonspecific indicators of cardiac damage. Exploring new, more specific biomarkers with a clear link to the underlying pathomechanism of cardiotoxicity holds promise for increased specificity and sensitivity in detecting early anthracycline-induced cardiotoxicity. miRNAs (microRNAs), small single-stranded, noncoding RNA sequences involved in epigenetic regulation, influence various physiological and pathological processes by targeting expression and translation. Emerging as new biomarker candidates, circulating miRNAs exhibit resistance to degradation and offer a direct pathomechanistic link. This review comprehensively outlines their potential as early biomarkers for cardiotoxicity and their pathomechanistic link.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 2","pages":"Pages 183-199"},"PeriodicalIF":12.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324000127/pdfft?md5=265bcc23dd36424e8f07ecb4b818deec&pid=1-s2.0-S2666087324000127-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jacc: Cardiooncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666087324000127","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Close monitoring for cardiotoxicity during anthracycline chemotherapy is crucial for early diagnosis and therapy guidance. Currently, monitoring relies on cardiac imaging and serial measurement of cardiac biomarkers like cardiac troponin and natriuretic peptides. However, these conventional biomarkers are nonspecific indicators of cardiac damage. Exploring new, more specific biomarkers with a clear link to the underlying pathomechanism of cardiotoxicity holds promise for increased specificity and sensitivity in detecting early anthracycline-induced cardiotoxicity. miRNAs (microRNAs), small single-stranded, noncoding RNA sequences involved in epigenetic regulation, influence various physiological and pathological processes by targeting expression and translation. Emerging as new biomarker candidates, circulating miRNAs exhibit resistance to degradation and offer a direct pathomechanistic link. This review comprehensively outlines their potential as early biomarkers for cardiotoxicity and their pathomechanistic link.

查看原文本刊更多论文

循环微RNA作为蒽环类药物诱发心脏毒性的生物标记物

密切监测蒽环类化疗期间的心脏毒性对早期诊断和治疗指导至关重要。目前，监测主要依靠心脏成像和连续测量心肌肌钙蛋白和钠尿肽等心脏生物标志物。然而，这些传统的生物标志物是心脏损伤的非特异性指标。miRNA（微RNA）是参与表观遗传调控的小型单链非编码 RNA 序列，通过靶向表达和翻译影响各种生理和病理过程。作为新的候选生物标志物，循环中的 miRNA 具有抗降解性，可提供直接的病理机制联系。本综述全面概述了 miRNA 作为心脏毒性早期生物标记物的潜力及其与病理机制的联系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Jacc: Cardiooncology Multiple-

CiteScore

12.50

自引率

6.30%

发文量

106

期刊介绍： JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge. The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention. Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.